TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cmax of fenofibric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: categorized Schirmer values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blurred vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median time to relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of opioid-negative urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in social concerns related to infertility distress
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Feeling more informed about medical decision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increased infertility self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: behavioral decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptom scores (Borg score)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Peak flow (morning, evening, and variability)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) of the lumbar spine and radius
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High density lipoprotein cholesterol (HDL-c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Antiretroviral adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serum ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Estimated financial cost to start-up and run IPTi
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of bleeding related to out-of-bed activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of palpitation episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of anxious patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete satisfaction with preoperative education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived knowledge after MME
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Level of E-selectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Risk of new vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean reduction in MADRS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: claudication distances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simultaneous radiographic and clinical success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less catheter placement without a wire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shorter time to proper catheter positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 36-week Hct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of transfusions per subject
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS II+III score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum walking capacity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: shear bond strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test time reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repletion of 25(OH)D levels ≥30 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients with an IFN signature response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Excess mortality in the hypothermia group
Endpoint domain: Mortality/survival
Primary endpoint: Unfavorable outcome at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Wound leaks
Endpoint domain: Adverse events/effects
Primary endpoint: Activation of the dorsolateral prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pa latency during anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall survival at five years
Endpoint domain: Mortality/survival
Primary endpoint: Failure-free survival at five years
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of NVJs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activity in the medial prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Comfort level of CS regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Convenience of CS and CSM regimens
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CRs (complete responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric contraction amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency and velocity of gastric contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Knee Society score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain and function subscores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra-individual plasma exposure (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of bifidobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days of tooth sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of FG score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in fasting insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of redislocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of severe hypovitaminosis D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum BCX AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Zeaxanthin AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnea-hypopnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall RQLQ score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Symptom scores reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication requirements reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase in sIL-2R alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tolerability of IL-2 treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative patency rates at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cumulative survival at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Discontinuation of therapy due to gastrointestinal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: composite alcohol scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CYP3A-mediated midazolam metabolism clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of treatment goals for vascular risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: L/M ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting plasma glucose (FPG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptomatic hypoglycemia episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Nocturnal hypoglycemia episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Serum dopamine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: improvements in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of guanfacine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of guanfacine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-infinity) of guanfacine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core cooling rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Threshold for shivering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semaglutide exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Major hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: rate of overall infectious complications
Endpoint domain: Adverse events/effects
Primary endpoint: infection-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients switching from 'off' to 'on'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from 'off' to 'on' post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: respiratory comfort score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: sustained virological response (SVR) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity to pinprick
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain rating after electrical stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure pain tolerance threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constant‐Murley score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CFA values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNA values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relatives' satisfaction with care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intact GLP-1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 24-hour opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of recovery using the Quality of Recovery Questionnaire (QoR-40)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: GIS global score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: renal volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Limits of quantitation for quinapril and quinaprilat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra- and inter-day variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of analytes in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour summed pain intensity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's Global Evaluation of Study Medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: survival at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Success rate at 1 year after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Test score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of cardiovascular death, MI, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Hospitalizations for ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Moderate bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: spontaneous pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rectal examination pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGD2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LTB4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: caregiver perceptions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IgG titers against glycoprotein (gp) 70V1V2 92TH023
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative incidence of urinary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of SSI events
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life (QOL)
Endpoint domain: Life impact
Primary endpoint: Tracheal temperature increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total water content increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median MBF in the infarct‐related territory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tHcy concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: T lymphocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Monocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Soluble ICAM-1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total prednisolone dose
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Primary BLE duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secondary BLE incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall cognitive performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional capacity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 24-h plasma glucose AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monthly rate of nocturnal hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Fall in serum LH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: freedom from any arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lung gas exchange capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ongoing pregnancy rate per started cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: oocyte yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: percentage of LDL-C reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma renin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma aldosterone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma adrenocorticotrophic hormone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Resting LV ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total peripheral resistance during peak exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke volume at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visualization of gastrointestinal tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Distension of stomach and small bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ED(90) of oxytocin for satisfactory uterine tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall in mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: regression of EH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hysterectomy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ischemic stroke within 30 days of angioplasty and stenting
Endpoint domain: Adverse events/effects
Primary endpoint: Subarachnoid hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Delayed intraparenchymal hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder-tip pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myeloperoxidase activity (MPO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CH50 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decline in lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracheal intubation performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: lunchtime intakes of energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lunchtime intakes of total fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: customer satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Survival for 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Overall costs of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: BMI loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decline in serum ALT activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: HIV RNA level <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfect adherence at week 96
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: mean flare measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical inflammatory assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy Eating Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: compliance with physical activity guidelines
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ulcer pain reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to achieve 75-100% granulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve ≥ 50% re-epithelialisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of PEX syndrome
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of OAG
Endpoint domain: Mortality/survival
Primary endpoint: Counseling steps implementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bending stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pull-out strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean time to flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean time to defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean time to the ability to tolerate food
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Femoral tunnel diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes